Biocryst Pharmaceuticals (BCRX) Short-term Investments (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Short-term Investments data on file, last reported at $66.8 million in Q1 2026.

• Quarterly Short-term Investments fell 64.82% year-over-year to $66.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.8 million (down 64.82% YoY) and the FY2025 annual result came in at $185.0 million, down 14.4% from the prior year.
• Short-term Investments retreated to $66.8 million in Q1 2026, from $185.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $278.3 million in Q4 2023 to a low of $48.0 million in Q1 2022.
• A 5-year average of $186.0 million and a median of $189.9 million in 2025 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 3621.76% — and 2026, when it tumbled 64.82%.
• Tracing BCRX's Short-term Investments over 5 years: stood at $119.5 million in 2022, then surged by 132.84% to $278.3 million in 2023, then retreated by 22.35% to $216.1 million in 2024, then declined by 14.4% to $185.0 million in 2025, then plunged by 63.89% to $66.8 million in 2026.
• The last three Short-term Investments figures came in at $66.8 million (Q1 2026), $185.0 million (Q4 2025), and $128.8 million (Q3 2025), per Business Quant data.